Article

Combination therapy improves both pain and depression

For patients who have comorbid depression and musculoskeletal pain, optimized antidepressant therapy combined with pain self-management may result in substantial improvements in both conditions. However, additional interventions may be needed to achieve bigger improvements in pain and higher depression response and remission rates.

For patients who have comorbid depression and musculoskeletal pain, optimized antidepressant therapy combined with pain self-management may result in substantial improvements in both conditions. However, additional interventions may be needed to achieve bigger improvements in pain and higher depression response and remission rates.

Kroenke and colleagues studied 250 primary care patients who had had at least moderately severe low back, hip, or knee pain for at least 3 months and were at least moderately depressed. Patients were randomized to usual care or stepped care: 12 weeks of antidepressant therapy; then 6 sessions of pain self-management (social support, behavioral modification, relaxation techniques), practiced over 12 weeks; then 6 months of continuation and follow-up. The primary study outcomes were depression and pain severity at 1 year.

At 12 months, pain was reduced by at least 30% in 41.5% of the intervention group versus 17.3% of the usual-care group. Depression was cut by at least 50% in 37.4% of the stepped-care versus 16.5% of the usual-care group. More patients receiving stepped care (26%) rather than usual care (7.9%) also reported feeling both happier and more comfortable.

The authors noted that because pain and depression are leading causes of decreased work productivity, an intervention that is effective for both may be useful.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.